; and (2) incorporate climate risk into policies related to transparency, labeling, and other regulatory policies related to drugs and devices, based on the recommendations of the task force described in subsection (a). (c) Authorization of appropriations There is authorized to be appropriated to carry out this section $4,000,000 for fiscal year 2024, to remain available until expended. . 403. Green health care manufacturing (a) In general There is established a Federal interagency working group, to be known as the Council on Green Health Care Manufacturing (referred to in this section as the Council ). (b) Membership The membership of the Council shall consist of— (1) the Secretary of Health and Human Services (referred to in this section as the Secretary ), who shall serve as the Chair; (2) the Secretary of Energy; (3) the Secretary of Transportation; (4) the Secretary of Labor; (5) the Administrator of the Environmental Protection Agency; (6) the Director of the Office of Climate Change and Health Equity; (7) the Director of Sustainability and Environmental Impact; (8) the Chair of the Council on Environmental Quality; (9) the United States Trade Representative; and (10) the heads of other Federal agencies, as determined necessary by the Chair. (c) Duties (1) Assessment and report (A) In general Not later than 1 year after the date of enactment of this Act, the Council shall conduct an assessment of global and domestic medical supply chains, including an assessment of— (i) the environmental and climate impacts of medical supply chains, including— (I) emissions from the production, transportation, and packaging of medical and pharmaceutical products; (II) chemical and other environmental pollution; (III) excessive energy consumption; (IV) negative externalities relating to waste; and (V) any other environmental or climate impacts the Council determines relevant